Tag Archives: section 3(d)

Indian Civil Society Members Urge Prime Minister to Resist US Administration Pressure

March 27, 2014 Dr. Manmohan Singh Hon’ble Prime Minister of India, The Prime Minister’s Office, South Block, Raisina Hill, New Delhi 110011. Tel: 011 23018939; Fax: 011 2301 0233. Email: manmohan@sansad.nic.in Resist the US administration Pressure and Reject the Misleading

Valganciclovir: IPAB remands matter back to the Controller: patent to remain revoked

30th January, 2014: The Intellectual Property Appellate Board (IPAB) set aside the Patent Controller’s decision to revoke the patent relating to valganciclovir on technical grounds and remanded it to the Controller for re-consideration. In a significant development for patient groups,

Lawyers Collective Response to Testimony of Mr. Roy F Waldron, Pfizer Inc.

Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a hearing, ‘A tangle

Analysing the Novartis Story

Vol – XLVIII No. 32, August 10, 2013 | Anand Grover A detailed account of the examination of Section 3(d) of the Indian Patents Act in the Supreme Court’s judgment on Novartis’s patent application for Glivec. Anand Grover (anandgrover@gmail.com) is a Senior

Attack on affordable medicines continues in EU-India trade negotiations

Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world  10 April, 2013, New Delhi­- Thousands of people living with HIV, cancer patient groups & public health activists rallied

Apex court right to reject Novartis’s attempt

Novartis  threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent

South Korean civil society groups welcome the ruling of the Supreme Court of India

[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and

Strictest patent laws will foster genuine innovation

In 2005, as the Indian Parliament debated at length the impact of complying with the WTO’s TRIPS Agreement, one issue was uppermost in their minds; the impact of granting patents on access to affordable generic medicines. And, the one medicine